Compare AIRG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | TCRX |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3M | 75.1M |
| IPO Year | 2016 | 2021 |
| Metric | AIRG | TCRX |
|---|---|---|
| Price | $6.94 | $1.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.25 | ★ $7.00 |
| AVG Volume (30 Days) | 115.8K | ★ 639.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,779,000.00 | $10,325,000.00 |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | $19.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.00 | $0.88 |
| 52 Week High | $7.39 | $2.57 |
| Indicator | AIRG | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 44.61 |
| Support Level | $3.93 | $0.91 |
| Resistance Level | $7.39 | $1.17 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 67.47 | 43.44 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.